2192 (2192) Fair Value & Analysis

Healthcare · Market cap HK$5.3B

2 2192 2192 · HK

PriceHK$7.10

Fair ValueHK$6.68

Upside-5.9%

Quality60/100

Watch 2192 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$6.30 – HK$7.27

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −7.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$6.48 – HK$15.82 · fair‑value band HK$6.30 – HK$7.27 · the HK$7.10 price screens above the HK$6.68 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2192 (2192) currently trades at HK$7.10, while our model-based Fair Value estimate is HK$6.68 — implying the stock looks roughly 5.9% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2192 generated revenue of HK$642M at a net margin of 52.1%. Revenue grew 4.8% year over year. It earns a return on equity of 7.1%. The balance sheet holds a net cash position of HK$2.6B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$642M

Revenue growth (YoY) +4.8%

Net margin 52.1%

Return on equity 7.1%

Free cash flow HK$122M FY2025

P/E ratio 13.7

More key figures

Operating margin 30.1%

EPS (TTM) HK$0.2100

Dividend yield 3.8%

EPS growth (YoY) +6.2%

Net cash HK$2.6B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2192 reported revenue of HK$642M in FY2025 versus HK$284M in FY2021, a compound +22.6%/yr. Reported net income was HK$334M in FY2025, compounding +69.4%/yr from FY2021.

Revenue +22.6%/yr

FY21 HK$284M

FY22 HK$314M

FY23 HK$412M

FY24 HK$558M

FY25 HK$642M

Net income +69.4%/yr

FY21 HK$40.6M

FY22 HK$117M

FY23 HK$242M

FY24 HK$315M

FY25 HK$334M

Is 2192 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$153.16	$183.66	+20%
Pro Medicus Limited PME	A$165.64	A$28.02	-83%
BrightSpring Health Services, Inc BTSG	$60.59	$23.87	-61%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$84.61	$79.57	-6%
M3, Inc MTHRY	$5.21	$7.47	+43%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2192 (2192) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$6.68 versus a price of HK$7.10 — about −6% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2192?

Our model-based fair value for 2192 is HK$6.68 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$7.10.

What is the quality score of 2192?

2192 has a Quality Score of 60/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2192 (2192)?

2192 reported trailing-twelve-month revenue of about HK$642M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2192?

The net profit margin of 2192 is about 52.1%, meaning it keeps roughly 52.1% of revenue as net income. Based on the latest reported figures.

Does 2192 pay a dividend?

2192 currently shows a dividend yield of about 3.82% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.